Factor XII Osaka: Abnormal factor XII with partially defective prekallikrein cleavage activity

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 473-478

  Iijima, Kenji ^a   Arakawa, Yuya ^a   Sugahara, Yuya ^a   Matsushita, Michiko ^a   Moriguchi, Yuki ^a   Shimohiro, Hisashi ^a   Nakagawa, Mayumi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Amino acid substitution; Catalytic domain; Chromogenic substrate; F12 haplotype; Intrinsic coagulation pathway

Indexed keywords

ALANINE; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; GLUTAMIC ACID; GLYCINE; PREKALLIKREIN; PROLINE; SERINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING FACTOR 12 DEFICIENCY; CASE REPORT; EXON; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; JAPANESE; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION;

ADULT; BLOOD COAGULATION; CATALYTIC DOMAIN; EXONS; FACTOR XII; FACTOR XII DEFICIENCY; HAPLOTYPES; HETEROZYGOTE; HUMANS; KALLIKREINS; MALE; MUTATION; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 79952507041     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0123     Document Type: Article

References (19)

1. Cool DE, Edgell C-J, Louie GV, et al. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of β-factor XIIa. J Biol Chem 1985; 260: 13666-13676. (Pubitemid 16233218)
2. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257: 1779-1784. (Pubitemid 12157124)
3. Wuepper KD, Cochrane CG. Plasma prekallikrein: Isolation, characterization, and mechanism of action. J Exp Med 1972; 135: 1-20.
4. Schmaier AH and LaRusch G. Factor XII: New life for an old protein. Thromb Haemost 2010; 104: 915-918.
5. Cool DE, MacGillivray RTA. Characterization of the human blood coagulation factor XII gene: Intron/exon gene organization and analysis of the 5′- flanking region. J Biol Chem 1987; 262: 13662-13673. (Pubitemid 17144310)
6. Human Gene Mutation Database. Available at: http://www.hgmd.cf.ac.uk/ac/ all.php.
7. Feng Y, Ye X, Pang Y, Dai J, et al. A novel mutation in a patient with congenital coagulation factor XII deficiency. Chinese Med J 2008; 121: 1241-1244.
8. Lombardi AM, Bortoletto E, Scarparo P, Scapin M, et al. Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13(Q501STOP), exon 14 (P547L) and -13>T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis 2008; 19: 639-643.
9. Miyata T, Kawabata S, Iwanaga S, et al. Coagulation factor XII (Hageman factor) Washington D.C.: Inactive factor XIIa results from Cys-571→Ser substitution. Proc Natl Acad Sci USA 1989; 86: 8319-8332.
10. Wuillemin WA, Furlan M, Stricker H, et al. Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma. Thromb Haemost 1992; 67: 219-225.
11. Schloesser M, Zeerleder S, Lutze G, et al. Mutations in the human factor XII gene. Blood 1977; 90: 3967-3977.
12. Kondo S, Tokunaga F, Kawano S, et al. Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 1999; 93: 4300-4308. (Pubitemid 29279273)
13. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014. (Pubitemid 28185502)
14. Saito H, Scott JG, Movat HZ, et al. Molecular heterogeneity of Hageman trait (factor XII deficiency). Evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Clin Med 1979; 94: 256-265. (Pubitemid 10208511)
15. +) factor XII deficiency. Thromb Haemost 1981; 54: 120 (Abstract).
16. Takahashi I, Saito H. A rapid purification with high recovery of factor XII (Hageman factor) on immunoaffinity column: Application to an abnormal clotting factor XII (Factor XII Toronto). J Biochem 1988; 103: 641-643.
17. Wuillemin WA, Furlan HM, Lämmle B. Functional characterization of an abnormal factor XII molecule (F XII Bern). Blood 1991; 78: 997-1004.
18. Hovinga JK, Schaller J, Stricker H, et al. Coagulation factor XII Locarno: The functional defect is caused by the amino acid substitution Arg353→Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173-1181. (Pubitemid 24245882)
19. Hoem N-O, Johannesen S, Briseid K. Assay of factor XII in human plasma using prekallikrein or the chromogenic peptide S-2222 as substrates - significance of the functional state of plasma kallikrein. Thromb Res 1989; 54: 197-205. (Pubitemid 19140509)